Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-28
2006-02-28
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S385000, C514S002600
Reexamination Certificate
active
07005414
ABSTRACT:
According to the claims, the present invention comprises the preparation of chemically modified, cross-linked hemoglobins with improved functional properties, the cross-linked hemoglobins prepared according to this method and the use of these hemoglobins as artificial oxygen carriers. The synthesis method is characterized by technical simplicity as well as by high yields.Deoxygenated hemoglobin of high purity is conjugated covalently under the protection of an antioxidant with an effector of oxygen binding, especially with pyridoxal-5-phosphate, after which the hemoglobin is polymerized with glutardialdehyde as a bifunctional cross-linking agent. At the same time, there is a large increase in the volume of the reaction mixture and a decrease in the concentration of the hemoglobin during the addition of the cross-linking agent. Subsequently, after further dilution with water, a polyethylene oxide derivative is chemically linked to the cross-linked hemoglobins. Polymers are obtained, which are compatible with blood plasma and have optimized cooperativity and half saturation pressure values and can find use as artificial oxygen carriers and, in particular, are divided into a lower molecular weight fraction as blood substitute and a higher molecular weight fraction as blood additive, for example, for the treatment of oxygen-deficiency conditions.
REFERENCES:
patent: 4001200 (1977-01-01), Bonsen et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4179637 (1979-12-01), Santora
patent: 4857636 (1989-08-01), Hsia
patent: 5380824 (1995-01-01), Marschall et al.
patent: 5386014 (1995-01-01), Nho et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5478805 (1995-12-01), Shorr et al.
patent: 449 885 (1927-09-01), None
patent: 0 26 07 706 (1976-09-01), None
patent: 2616 086 (1977-11-01), None
patent: 30 26 398 (1981-03-01), None
patent: 0 31 30 770 (1983-03-01), None
patent: 0 067 029 (1982-12-01), None
patent: 0206 448 (1986-12-01), None
patent: 0 221 618 (1987-05-01), None
patent: 0 854 151 (1998-07-01), None
patent: WO 91/07190 (1991-05-01), None
patent: WO 91/16352 (1991-10-01), None
XP002182224—Azhigirova M. Alekseevna et al: “Production of artificial oxygen carrier—using a Haemoglobin Solution, Useful in Establishing Erythrocyte Substitute Based on Chemically Modified Haemoglobin”, Oct. 2, 1997.
XP-0010337782—Poetzschke H et al: “Molar Masses and Structure in Solution of Haemoglobin Hyper-Polymers—a Common Calibration of Size Exclusion Chromatography of these Artificial Oxygen Carriers” Artificial Cells Blood Substitutes and Immobilization Biotechnology, 25(6), 527-540 (1997).
XP-001029599—Haney Chad R., et al: “Purification and Chemical Modifications of Hemoglobin in Developing Hemoglobin Based Oxygen Carriers” Advanced Drug Delivery Reviews 40 (2000) 153-164.
Fitzgerald, L. R; “Cutaneous Respiration in Man”; Cutaneous Respirtion, Division of Anatomy, University of Tennessee Medical Units, Memphis, TN, Jul. 1957, pp. 325-336, vol. 37.
Barnikol, W. K.R.et al; “Die Feinstruktur der Sauerstoff-Hämoblogin-Bindung als Hilfsmittel zum Studium pharmakologischer Wirkungen . . . ”; Physiologisches Institut der Johannes Guttenberg-Germany, Funkt. Biol. med. 2, (1983), pp. 245-249.
Kothe, N., et al.; “Characterization of a modified, stroma-free hemoglovin solution as an oxygen-carrying plasma substitute”; Scientific Department of Biotest Pharma GmbH, Frankfurt, Germany; Surgery, Gynecology & Obstertrics, Dec. 1985, vol. 161, pp. 563-569.
Bosman, R.J. et al. “Free Polymerized Hemoglobin Versus Hydroxyethyl Starch in Resuscitation of Hypovolemic Dogs”, Anesth. Analg. 75, pp. 811-817.
Pabst, R.; “Sauerstofftransport mit stromafreien Hämoglobinlösungen und Fluorocarbonen”; Med. Klin. 72 (1977) pp. 1555-1562, vol. 39.
Chang, T.M.S., “How safe are modified hemoglobins?” Blood Substitutes: Present and Future Perspectives, Elsevier Science, Amsterdam (1998).
Keipert, et al, “Pyridoxylated Polyhemoglobin as a red cell substitute for resuscitation of lethal hemorrhagic shock in conscious rats”; Biomat. Med. Dev. Art. Org. 13 (1&2), pp. 1-15 (1935).
Hirlinger, W.K., et al, “Effects of a Partial Exchange with Fluosol DA 20% on healthy Pig”, Anästhesist 31, pp. 660-666 (1982).
Keipert, et al; “Pyridoxylated-polyhemoglobin solution: a low viscosity oxygen-delivering blood replacement fluid with normal oncotic pressure and long-term storage feasibility”; Artificial Cells & Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Canada, pp. 185-197.
Hunt, C.A., et al., “Synthesis and Evaluation of a Protypal Artificial Red Cell”, Science, 230: pp. 1165-1168 (1985).
Farmer, M.C.; et al; “Preclinical data and clinical trials with diaspirin cross-linked hemoglobin”; Artificial Red Cells, edited by E. Tsuchida, (1995) John Wiley and Sons pp. 177-185.
Keipert P.E., et al, “Metabolism, Distribution, and Excretion of HbXL: A Nondissociation Interdimerically Crosslinked Hemoglobin with Exceptional Oxygen Offloading Capability”, Chang, T.M.S., Geyer R. P.(Eds.): Blood Substitutes, Marcel Dekker, New York (1989).
Chang T.M.S., “Modified Hemoglobin as Red Cell Blood Substitutes”, Biomat. Art. Cells, Art. Org. 15(2), pp. 323-328 (1987).
Friedman H.J., et al, “In Vivo Evaluation of Pyridoxylated-Polymerized Hemoglobin Solution”, Surg. Gynecol., Obstet.: 159, pp. 429-435 (1984).
Bakker, J.C. et al; “Properties of hemoglobin interdimerically cross-linked with NFPLP”; Biomet. Art. Cells & Immob. Bio., vol. 16, pp. 635-636 (1988).
Barnikol, W.K.R. et al, “Hyperpolymeric Hemoglobins and Artifical Oxygen Carriers. An Innovative Attempt at Medical Development”, Therapiewoche 46: pp. 811-815 (1996).
Pötzschke, H. et al; “Vernetzte globuläre proteine—eine neue klasse halbsynthetischer makromoleküle: . . . ”; Macromol. Chem. Phys. 197, pp. 1419-1437 (1996).
Barnikol, W.K.R., “the Influence of Glutardialdehyde on the Oxygen Cooperativity of Human Hemoglobin”, Pflügers Archi 406: R 61 (1986).
Conover et al, “The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models”; Art. Cells, Blood Subst. Immobil. Biotech. 27: pp. 93-107 (1999).
Looker, D. et al; “A human recombinant haemoglobin designed for use as a blood substitute”; Nature. vol. 356, Mar. 19, 1992; pp. 258-260.
Xue, H. et al; “Preparation of conjugated hemoglobins”; Methods in Enzymology, vol. 231, pp. 308-332 (1994).
Barnikol, W. K. R., et al; “Highly polymerized human haemoglobin as an oxygen-carrying blood substitute”, Advances in Experimental Medicine and Biology, vol. 215, pp. 129-134 (1987).
Tam, et al; “Blood replacement in dogs by dextran-hemoglobin”; Can. J. Biochem, vol. 56, (1978); pp. 981-984.
Gould, et al; “The clinical development of human polymerized hemoglobin”; Blood Substitutes: principles, methods, products and clinical trials, edited by Thomas Ming Swi Chang (1998).
Bakker, et al; “Preparation and characterization of crosslinked and polymerized hemoglobin solutions”; Biomat., Art. Cells & Immob. Biotec., 20(2-4), pp. 233-241 (1992).
“Points to consider in the safety evaluation of hemoglobin-based oxygen carriers”; Center for Biologies Evaluation and Research; Transfusion vol. 31, 4 (1991) pp. 369-371.
Pötzschke, H. et al “A novel method for determining molecular weights of widely distributed polymers with the help of gel photography and viscosimetry using hemoglobin hyperpolymers as examples”, Macromolecular chemistry and Physics 197, pp. 3229-3250 (1996).
Barnikol, W.K.R. et al, “An improved modificati
Barnikol Wolfgang
Burkhard Oswald
Dinkelmann Stephanie
Domack Ulrike
Fiedler Bernd
Mondesi Robert B.
Norris McLaughlin & Marcus PA
Sanguibiotech GmbH
Wax Robert A.
LandOfFree
Synthetic oxygen transport made from cross-linked modified... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic oxygen transport made from cross-linked modified..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic oxygen transport made from cross-linked modified... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3669150